CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Summary

DelveInsight’s, “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Understanding

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview

Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy characterized by the clonal proliferation of immature lymphoid cells, resulting in suppression of normal bone marrow hematopoiesis. It is classified into B-cell and T-cell subtypes, with precursor B-cell ALL (B-ALL) accounting for the majority of cases, while T-cell ALL is generally more aggressive. Although combination chemotherapy, corticosteroids, and allogeneic stem cell transplantation have improved long-term survival, particularly in pediatric patients, relapse or refractory disease remains a major clinical challenge, occurring in up to 20% of children and with substantially poorer outcomes in adults. The limited survival following relapse has driven the development of novel treatment strategies, among which chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising option for patients with relapsed or refractory ALL.

CAR T-cell manufacturing begins with the collection of peripheral blood mononuclear cells from either the patient (autologous) or a healthy donor (allogeneic) through leukapheresis. T cells are then isolated and activated using anti-CD3/anti-CD28 antibodies or artificial antigen-presenting cells, often with cytokines such as IL-2 to enhance proliferation. The activated T cells are genetically engineered to express the chimeric antigen receptor (CAR), typically using lentiviral vectors due to their favorable safety profile, although non-viral gene transfer methods may also be employed. The modified CAR T cells are subsequently expanded, characterized for quality, cryopreserved, and prepared for infusion into the patient.

Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), producing high remission rates; however, relapse following an initial response remains a major limitation. A systematic review and meta-analysis comparing different CAR T-cell constructs found that therapies incorporating the 4-1BB co-stimulatory domain achieved deeper and more durable remissions with a lower incidence of immune effector cell-associated neurotoxicity than CD28-based constructs. Additionally, CD19- and CD19/CD22-targeted CAR T-cell therapies demonstrated superior efficacy compared with CD22-targeted approaches, highlighting 4-1BB-based CD19 CAR T-cell therapy as the most favorable strategy in terms of both efficacy and safety for patients with R/R B-ALL.

Several surface antigens have been explored as targets for CAR T-cell therapy in acute lymphoblastic leukemia (ALL), with CD19 remaining the primary target in B-cell ALL (B-ALL) because of its consistent expression on malignant B cells and absence on hematopoietic stem cells. Although CD19-directed therapy may cause prolonged B-cell aplasia and hypogammaglobulinemia, it has demonstrated substantial clinical benefit in relapsed/refractory disease. To date, the FDA has approved KYMRIAH, TECARTUS, BREYANZI, and YESCARTA for adults with relapsed/refractory B-ALL. Other antigens under investigation include CD20 and thymic stromal lymphopoietin receptor (TSLPR) for B-ALL, and CD7 and CD38 for T-cell ALL. In addition, next-generation CAR T-cell therapies incorporating dual or multiple antigen targets are being developed to overcome antigen escape and reduce on-target, off-tumor toxicities.

Despite significant advances over the past three decades, CAR T-cell therapy continues to evolve to address limitations such as lengthy manufacturing times, treatment resistance, antigen escape, and therapy-related toxicities. The development of off-the-shelf allogeneic CAR T-cell therapies aims to provide readily available, high-quality donor-derived cells, enabling faster treatment and scalable manufacturing compared with autologous products. However, challenges such as graft rejection and graft-versus-host disease (GVHD) remain, prompting the development of innovative strategies including gene editing, immune evasion technologies, alloimmune defense receptors, and the use of ?? T cells to improve compatibility and persistence. Alternative immune effector cells, such as natural killer (NK) cells and macrophages, are also being explored as CAR platforms because of their lower risk of GVHD, favorable safety profile, and potential to overcome tumor immune evasion. Concurrently, next-generation CAR T-cell therapies are expanding beyond CD19 to target antigens such as CD20, CD22, BCMA, CD123, and BAFF-R, while dual- and multi-antigen targeting strategies, as well as sequential CAR T-cell infusions, are being investigated to reduce antigen-loss relapse, enhance antitumor efficacy, and achieve more durable clinical responses in acute lymphoblastic leukemia.

"CAR T-Cell Therapy for Acute Lymphoblastic Leukemia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Acute Lymphoblastic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Acute Lymphoblastic Leukemia.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs Chapters

This segment of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs

• CAR-T-19 cell injection: Immunotech Biopharma

CAR-T-19 cell injection, developed by Beijing Yongtai Ruike Biotechnology Company Ltd., is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being evaluated for the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in pediatric and young adult patients (?25 years). The therapy involves collecting a patient's T cells, genetically engineering them to express a CD19-specific CAR, and reinfusing them following lymphodepleting chemotherapy, enabling targeted recognition and destruction of malignant B cells while providing sustained anti-tumor immune activity. Currently in Phase II clinical development, the therapy aims to improve remission rates and address the unmet medical need in patients with relapsed or refractory B-ALL who have limited treatment options.

• WU-CART-007: Allotera Therapeutics

WU-CART-007, originally developed by Wugen (now Allotera Therapeutics), is an investigational allogeneic, off-the-shelf, anti-CD7 CAR-T cell therapy being developed for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The therapy utilizes healthy donor-derived T cells that are CRISPR/Cas9 gene-edited to delete CD7 and the T-cell receptor alpha constant (TRAC) genes, preventing CAR-T cell fratricide and reducing the risk of graft-versus-host disease (GvHD). By targeting CD7-expressing malignant T cells, WU-CART-007 aims to provide a readily available treatment option without the manufacturing delays associated with autologous CAR-T therapies. The therapy has demonstrated encouraging anti-leukemic activity and a manageable safety profile in clinical studies and is currently being evaluated in a global Phase II pivotal trial for patients with relapsed/refractory T-ALL/T-LBL.

• TBI-1501: Takara Bio

TBI-1501, developed by Takara Bio, is an investigational autologous anti-CD19 CAR-T cell therapy being developed for the treatment of relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). The therapy is manufactured by genetically modifying a patient's own T cells using Takara Bio's proprietary RetroNectin®-based gene transduction and T-cell expansion technology to express a CD19-specific chimeric antigen receptor, enabling targeted recognition and elimination of leukemic B cells. Following lymphodepleting chemotherapy with cyclophosphamide, TBI-1501 is administered as a single infusion and is currently being evaluated in a multicenter Phase I/II clinical trial in Japan to assess its safety, persistence, pharmacokinetics, and anti-tumor efficacy in patients with relapsed/refractory CD19-positive B-ALL.

• MC-1-50: Chongqing Precision Biotech Co., Ltd

MC-1-50, developed by Chongqing Precision Biotech Co., Ltd., is an investigational autologous CD19-targeted CAR-T cell therapy being developed for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). The therapy is manufactured using the company's proprietary PrimeCAR® platform, which shortens CAR-T cell production to approximately 2–3 days, enabling faster treatment while reducing manufacturing costs. MC-1-50 is designed to achieve durable anti-leukemic activity at lower cell doses with an improved safety profile, including reduced rates of cytokine release syndrome (CRS) and neurotoxicity. The therapy is currently being evaluated in a Phase I, open-label, dose-escalation clinical trial to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with relapsed/refractory B-ALL, following encouraging early clinical data demonstrating high complete remission rates and manageable toxicity.

Further product details are provided in the report……..

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Therapeutic Assessment

This segment of the report provides insights about the different CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
• There are approx. 30+ key companies which are developing the therapies for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia. The companies which have their CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drug candidates in the most advanced stage, i.e. Phase II include, Immunotech Biopharma.

• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Insights

• CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs?
• How many CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• miltenyibiomedicine
• TriArm Therapeutics (Taiwan) Limited
• PeproMene Bio, Inc.
• Hebei Senlang Biotechnology Inc., Ltd.
• Allotera Therapeutics
• Takara Bio
• Immunotech Biopharma
• Chongqing Precision Biotech Co., Ltd
• Beam Therapeutics
• OneChain Immunotherapeutics
• Imviva Biotech
• Hebei Senlang Biotechnology Inc., Ltd
• Fate Therapeutics
• Cellectis Editing Life

Key Products

• MB-CART19.1
• ARM011
• BAFFR-CAR T cells
• S1904 CD19 CAR-T
• WU-CART-007
• TBI-1501
• CAR-T-19 cell injection
• MC-1-50
• BEAM-201
• CD1a-CAR T
• OC-1
• OC-1D
• CTD402
• Autologous CD7-targeting CAR T cells
• FT819
• Lasme-cel